Chai Discovery develops frontier artificial‑intelligence platforms to predict and re‑program biochemical molecule interactions, focusing on de novo antibody design and drug‑like molecule engineering with atomic precision. Based in the United States, the company targets challenging therapeutic targets by combining AI‑driven molecular modeling with biophysical expertise to accelerate discovery of novel biologics.